^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    CANCER:

    Bladder Cancer

    Related cancers:
    20h
    A Study to Find Out if Enfortumab Vedotin Given With Pembrolizumab Helps People With Muscle-invasive Bladder Cancer Keep Their Bladder (clinicaltrials.gov)
    P2, N=240, Recruiting, Astellas Pharma Global Development, Inc. | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Keytruda (pembrolizumab) • Padcev (enfortumab vedotin-ejfv)
    21h
    ADAPT-BLADDER: Modern Immunotherapy in BCG-Unresponsive, BCG-Relapsing and High Risk BCG-Naive Non-Muscle Invasive Urothelial Carcinoma of the Bladder (clinicaltrials.gov)
    P1/2, N=55, Recruiting, Noah Hahn, M.D. | Trial completion date: Dec 2026 --> Dec 2027 | Trial primary completion date: Dec 2025 --> Dec 2026
    Trial completion date • Trial primary completion date
    |
    PD-L1 (Programmed death ligand 1)
    |
    Imfinzi (durvalumab) • gemcitabine • docetaxel • Imjudo (tremelimumab-actl)
    24h
    17000139BLC2002: A Phase 2, Open-Label, Multi-Center, Randomized Study of TAR-200 in Combination with Cetrelimab and Cetrelimab Alone in Participants with Muscle-Invasive Urothelial Carcinoma of the Bladder who are Scheduled for Radical Cystectomy and are Ineligible for or Refusing Platinum-Based Neoadjuvant Chemotherapy (2023-507189-17-00)
    P1/2, N=89, Completed, Janssen - Cilag International | Active, not recruiting --> Completed
    Trial completion
    |
    cetrelimab (JNJ-63723283) • Inlexzo (gemcitabine intravesical system)
    1d
    Concordance and prognostic value of antibody drug conjugate and checkpoint inhibition targets in matched bladder cancer specimens from transurethral resection of the bladder, radical cystectomy and lymphadenectomy. (PubMed, Urol Oncol)
    NECTIN-4 expression differs by tissue type, limiting prognostic value and supporting site-specific biomarker assessment in BC.
    Journal • Checkpoint inhibition • PD(L)-1 Biomarker • IO biomarker
    |
    HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1) • PD-1 (Programmed cell death 1) • NECTIN4 (Nectin Cell Adhesion Molecule 4) • TACSTD2 (Tumor Associated Calcium Signal Transducer 2)
    |
    HER-2 expression
    |
    Padcev (enfortumab vedotin-ejfv)
    1d
    Immunohistochemical Expression of p63 and GATA3 in Lymphomas of the Urinary Bladder: A Clinicopathologic Study of a Potential Diagnostic Pitfall. (PubMed, Int J Surg Pathol)
    These shared features constitute a significant diagnostic pitfall with potential therapeutic consequences. Awareness of this overlap and use of a broad immunohistochemical panel (eg, CD45, pankeratin) are essential for accurate diagnosis in unusual bladder tumors.
    Journal
    |
    PTPRC (Protein Tyrosine Phosphatase Receptor Type C) • TP63 (Tumor protein 63) • GATA3 (GATA binding protein 3)
    1d
    ESRP2 constrains EMT plasticity associated with ZEB1 expression in bladder cancer. (PubMed, Front Oncol)
    These findings identify ESRP2 as a key post-transcriptional regulator that constrains EMT-associated transcriptional programs linked to ZEB1 expression, thereby stabilizing epithelial identity in bladder cancer. Targeting alternative splicing may represent a promising therapeutic strategy to limit tumor aggressiveness and overcome treatment resistance.
    Journal
    |
    CD44 (CD44 Molecule) • ZEB1 (Zinc Finger E-box Binding Homeobox 1)
    1d
    MTHFD1L in muscle invasive bladder cancer: a multi-cohort study on prognosis and therapeutic response. (PubMed, World J Surg Oncol)
    MTHFD1L represents a promising and reliable biomarker for predicting prognosis and immunotherapy response in MIBC, providing a new foundation for the development of precision and personalized therapeutic strategies.
    Journal • IO biomarker
    |
    TP53 (Tumor protein P53)
    |
    TP53 mutation
    2d
    Tumor Budding and T1 Substaging in Urothelial Bladder Cancer (clinicaltrials.gov)
    P=N/A, N=100, Not yet recruiting, Assiut University
    New trial
    2d
    Mass Response of Tumor Cells as a Biomarker for Rapid Therapy Guidance (TraveraRTGx) (clinicaltrials.gov)
    P=N/A, N=72, Completed, Travera Inc | Recruiting --> Completed | N=200 --> 72 | Trial completion date: Jul 2028 --> Mar 2026 | Trial primary completion date: Jul 2027 --> Mar 2026
    Trial completion • Enrollment change • Trial completion date • Trial primary completion date
    2d
    Immune-Stromal Landscape in Muscle-Invasive Bladder Cancer (clinicaltrials.gov)
    P=N/A, N=100, Not yet recruiting, Assiut University
    New trial
    2d
    Nova-sTAR: A Study to Assess Real-World Use and Outcomes of TAR-200 for Participants With Non-Muscle Invasive Bladder Cancer (NMIBC) in the United States (clinicaltrials.gov)
    P=N/A, N=150, Recruiting, Janssen Research & Development, LLC | Trial completion date: Mar 2029 --> Oct 2029
    Trial completion date • Real-world evidence
    |
    Inlexzo (gemcitabine intravesical system)